Fairmount Fund Sells $133.5M in Apogee Therapeutics Shares, Reducing Stake
Summary
Fairmount Healthcare Fund II L.P., a major institutional investor with board representation, sold 1,750,000 shares of Apogee Therapeutics common stock for $133.5 million, reducing its stake to 9.82%.
Key Events
-
Significant Share Sale by Institutional Investor
Fairmount Healthcare Fund II L.P. sold 1,750,000 shares of Apogee Therapeutics common stock in a block trade on January 22, 2026.
-
Substantial Transaction Value
The shares were sold at $76.30 per share, totaling approximately $133.5 million.
-
Reduced Ownership Stake
Following the sale, Fairmount Healthcare Fund II L.P. and its affiliates now beneficially own 9.82% of Apogee Therapeutics' common stock, down from a previous stake of approximately 12.71%.
-
Board Representation
Peter Harwin and Tomas Kiselak, managing members of Fairmount Funds Management LLC, also serve on Apogee Therapeutics' board of directors.
Analysis
Fairmount Healthcare Fund II L.P., a significant institutional investor with managing members serving on Apogee Therapeutics' board, executed a substantial block trade, selling 1,750,000 shares of common stock for approximately $133.5 million. This sale represents a notable reduction in their overall position, decreasing their beneficial ownership to 9.82% of the company's common stock. While the fund remains a major shareholder, such a large disposition by a key institutional investor, especially one with board representation, could be interpreted by the market as a signal of reduced conviction or a strategic portfolio adjustment.
At the time of this filing, APGE was trading at $79.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $26.20 to $84.56. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.